MoneyWorks4Me

Biocon - Quaterly Results

28 Apr 2022 Evaluate
The company witnessed a 5.31% growth in the revenue at Rs. 5177.00 millions for the quarter ended March 2022 as compared to Rs. 4916.00 millions during the year-ago period.The Company to register a -43.72%  fall in the net profit for the quarter ended March 2022.Operating Profit reported a sharp decline to 873.00 millions from 1118.00 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 5177.00 4916.00 5.31 17382.00 20284.00 -14.31 17382.00 20284.00 -14.31
Other Income 608.00 449.00 35.41 1872.00 1502.00 24.63 1872.00 1502.00 24.63
PBIDT 873.00 1118.00 -21.91 2483.00 4627.00 -46.34 2483.00 4627.00 -46.34
Interest 0.00 1.00 0.00 4.00 4.00 0.00 4.00 4.00 0.00
PBDT 873.00 1117.00 -21.84 2479.00 4623.00 -46.38 2479.00 4623.00 -46.38
Depreciation 281.00 254.00 10.63 1082.00 1035.00 4.54 1082.00 1035.00 4.54
PBT 592.00 863.00 -31.40 1397.00 3588.00 -61.06 1397.00 3588.00 -61.06
TAX 211.00 186.00 13.44 536.00 783.00 -31.55 536.00 783.00 -31.55
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 381.00 677.00 -43.72 861.00 2805.00 -69.30 861.00 2805.00 -69.30
Equity 6003.00 6000.00 0.05 6003.00 6000.00 0.05 6003.00 6000.00 0.05
PBIDTM(%) 16.86 22.74 -25.85 14.28 22.81 -37.38 14.28 22.81 -37.38
Peers
Company Name CMP
Sun Pharma. Inds. 1782.00
Dr. Reddys Labs. 1208.00
Cipla 1334.00
Lupin 2010.00
Zydus Lifesciences 1138.50
View more..